A publication concerning survodutide appeared in the journal Diabetes, Obesity & Metabolism, dated November 2, 2026. The article is titled "Renal Effects of Dual GLP-1/Glucagon Receptor Agonism: How Should We SYNCHRONIZE With Emerging Evidence in Type 2 Diabetes and Obesity?" Survodutide remains classified as an unapproved research compound. The publication is indexed under PubMed ID 42972865 and is listed in the journal's records as a new entry. No findings, outcomes, or data from the publication were provided alongside this listing. This brief reports only that the publication exists and the bibliographic details associated with it, including its title, journal, and date of record. No efficacy, safety, or results information accompanies this notice. Readers interested in the substantive content of the article should consult the publication directly through the journal or the linked source. For general background on survodutide as a compound under investigation, readers can refer to the compound overview for additional context.
Survodutide Publication Examines Renal Effects in Diabetes, Obesity
See the full survodutide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42972865/